Great variations exist in the prophylaxis and treatment of GVHD in children undergoing allogeneic stem cell transplantation (SCT). The EBMT Working Party Paediatric Diseases (EBMT-WP PD) and the International BFM Study Group -Subcommittee Bone Marrow Transplantation (IBFM-SG), aimed at evaluating current local standards in the prevention and treatment of GVHD and steps which can be taken to achieve a uniform policy for the individual methods. Several conferences with their members assessed practices which are mainly applied or under investigation in children and identified where additional information is needed. For prevention of GVHD, the majority of the paediatric centres prefer CsA ± MTX. Addition of folinic acid to MTX was considered for reduction of side-effects. During treatment of acute GVHD most centres administer prednisolone and whole blood level-adjusted CsA as medications of first choice. In cases of poor or no response to this therapy, additional immunosuppressive agents such as ATG, mycophenolate-mofetile and tacrolimus are being increasingly used. The treatment of chronic GVHD usually consists of various combinations of prednisolone and CsA. In severe cases, extracorporeal photopheresis, psoralene-UVA (PUVA) and thalidomide are administered. Bone Marrow Transplantation (2000) 26, 405-411.
frequently than do older recipients of bone marrow transplants, 1 the risk of severe GVHD increases with the expanded use of HLA phenotypically different donors. 2, 3 The most effective approaches to prevent GVHD are lymphocyte depletion to remove effector cells from the graft, and separation of T cells from other accessory cells. However, these methods may result in increased engraftment failure and a weaker graft-versus-leukaemia (GVL) effect. 4 Thus, many paediatric SCT centres prefer GVHD prophylaxis by pharmacological means, using single or multiple immunosuppressive drugs. 5 In patients with malignant diseases, a major goal of allogeneic SCT is the immunologic GVL effect. 6 To maximise this reaction, it has been attempted to adapt GVHD prophylaxis to the needs of individual patients. 7, 8 Therefore, it is not surprising that many groups have developed individual protocols for the prevention and therapy of GVHD which renders an interpretation of pooled patient data difficult. [9] [10] [11] Response to primary GVHD therapy is one of the most important predictors of long-term survival. 12 Furthermore, in young children the impact of optimal GVHD therapy is important because the growing organism is vulnerable to the consequences of GVHD itself. 13, 14 So far only very few studies have been able to provide information about the efficacy of various therapeutic modalities used for the treatment of acute and chronic GVHD in childhood. [15] [16] [17] [18] Therefore, the members of the EBMT Working Party pediatric diseases (WP-PD) and of the International BFM Study Group -Subcommittee Bone Marrow Transplantation (IBFM-SG) determined what the individual strategies for GVHD prophylaxis and treatment in children have in common, suggested questions for future studies, and gave new centres the opportunity to learn about the experiences and results achieved by established groups. Furthermore, the application of uniform strategies among the different groups, aiming at the prevention and treatment of GVHD, should allow a more precise interpretation of study results in allogeneic stem cell transplantation. What follows is a summary of practical considerations which has been worked out by an international panel of paediatric experts in line with the literature available and data collected on current practices in this field.
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Methods
A proposal for GVHD prophylaxis and therapy in children 19 was mailed to all local representatives of the EBMT WP-PD and the IBFM-SG BMT. This was based on the results of a large survey within the European children transplantation centres. Parts of this survey have already been published, and other parts were presented orally. 20, 21 The wide heterogeneity of the answers obtained from this survey led to the attempt to work out proposals for some important indications for allogeneic stem cell transplantations in children, which can be justified in the light of the published literature, and which are, in fact, used by a majority of paediatric transplantation experts. These proposals were then thoroughly discussed at some large paediatric SCT meetings.
The proposal included stratification options for GVHD prophylaxis according to risk factors for the development of acute and chronic GVHD (eg donor source, age). Another issue focused on the desired GVL effect after allogeneic SCT.
The questions on GVHD therapy addressed the following issues: drugs and methods used for the treatment of mild and severe acute GVHD in children with malignant and non-malignant disorders, and first and second line treatment of limited or extensive GVHD.
The GVHD grading used for the proposal followed the guidelines of the Consensus conference on acute GVHD grading.
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Results
The following countries took part in the survey: Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Iceland, Israel, Italy, The Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Turkey, UK. All local representatives registered at the EBMT-working party pediatric diseases (EBMT WP-PD) and the International BFM Study Group -Subcommittee Bone Marrow Transplantation (IBFM SG-BMT) extensively discussed the common and different opinions within their countries and returned the original proposals with various additional suggestions and comments.
The following factors were considered for stratification of GVHD prophylaxis and treatment of acute GVHD: age of the patient, malignant or non-malignant underlying disease, type of donor (HLA-matched sibling donor (MSD) or HLA non-identical donor (NID)). Additionally, dosage and duration of use of the pharmacologic GVHD prophylaxis should be adjusted to the foreseeable GVHD risk, in order to increase the GVL effect, as well as to effectively avoid acute or chronic GVHD after SCT.
The majority of experts agreed on the following suggestions (for details see Table 1 and Table 2 ).
Administration of CsA
At the beginning of the transplantation procedure most centres prefer to administer CsA intravenously, twice a day, each infusion lasting for 2 h. Once oropharyngeal mucositis has resolved and oral intake is possible, CsA is given in twice the dose given by the intravenous route. In cases of toxic side-effects, most centres consider CsA levels and serum creatinine levels to be the main indicators of the severity of toxicity, and adjust the drugs according to trough levels. For CsA level monitoring whole blood rather than plasma should be used, and factors which affect the activity of the mixed function oxidase system cytochrome P-450 must be considered, ie liver dysfunction and many drugs.
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Administration of MTX Dosage: It is commonly agreed that MTX should be administered at a dose of 10 mg/m 2 . Also, most centres support the idea that, in cases where a paediatric patient is only at low risk of developing GVHD, he/she should either receive no MTX at all or just a very limited dose (ie on days +1, +3 and +6 after BMT). In cases of higher risk of GVHD, an additional dose of MTX on day +11 is given.
All responding centres agreed to the use of folinic acid after administration of MTX, to avoid side-effects such as myelosuppression and mucosal damage. The accepted dosage for folinic acid is 15 mg/m 2 /day, given 24 h after MTX administration. 
In vivo T cell antibodies
Many centres support the prophylactic use of polyclonal anti-lymphocyte antibodies from different companies (eg Imtix SangStat, Lyon, France; Fresenius, Bad Homburg, Germany; Upjohn Company, MI, USA) in patients at high risk of GVHD. The most frequently used dosage of the equine anti-thymocyte globulin (lymphoglobuline, Imtix; SangStat) was 20 mg/kg/day, given on days −3, −2 and −1.
The reported rabbit anti-thymocyte globulin (ATG; Fresenius) dose was 5-10 mg/kg/day given on days −5 to −1. Rabbit ATG (thymoglobuline, Imtix; Sangstat) has been recently used by different European teams as part of the conditioning regimen before allogeneic stem cell transplantation. Reported doses range between 2 mg/kg and 10 mg/kg 25 starting on day −5. Equine ATG (Atgam; Upjohn) is given on days −5, −4, −3 at a daily dose of 30 mg/kg in patients with SAA. 26 
T cell depletion
These methods are used only in children with a high GVHD risk.
Reduction and depletion of T cells were supported by 60% of the experts consulted. Different techniques are currently used: CD34 + positive selection (Clinimacs; Miltenyi, Bergisch Gladbach, Germany, 27 and Isolex; Baxter, Irvine, CA, USA 24 ) and T cell depletion using T cell antibodies (eg Campath, IG, IM). 28 
Risk-adapted prophylaxis strategies
GVHD prophylaxis for children with non-malignant disease and SCT from an HLA-matched sibling donor (relatively low risk of GVHD but no benefit from the GVL effect) was: CsA, initial intravenous dose 5 mg/kg/day day −1 until day +180, then dose reduction (10% of the initial GVHD prophylaxis for children with non-malignant disease and SCT from HLA-non-identical donors (high risk of GVHD, no benefit from GVL) was: (in addition to the above-mentioned regimen) polyclonal anti-human thymocyte globulins. An alternative approach for pharmacological immunosuppression was: T cell depletion (positive CD34 + cell selection, negative selection, E-rosetting, monoclonal antibodies).
GVHD prophylaxis for children with malignant disease and SCT from matched sibling donors (low risk of GVHD in young patients, strong suggestion for a GVL effectthus benefit from mild GVHD prophylaxis) was (1) children younger than 16 years of age: CsA, single drug prophylaxis (initial intravenous daily dose of 3 mg/kg (oral, 6 mg/kg) day −1 until day +100, then dose reduction (20% of the initial dose/week) in the absence of GVHD); (2) children older than 16 years of age: there was addition of a short course MTX to CsA (MTX, 10 mg/m 2 intravenously on days +1, +3 and +6; leucovorin, 15 mg/m 2 on days +2, +4 and +7).
GVHD prophylaxis for children with malignant disease and SCT from HLA-non-identical donors (high risk of GVHD) was: CsA, initial intravenous dose of 5 mg/kg/day until day +180, then dose reduction (10% of the initial dose/week) in the absence of GVHD; MTX, 10 mg/m 2 /day i.v. on days +1, +3, +6, +11; leucovorin, 15 mg/m 2 i.v. on days +2, +4, +7 and +12. Additionally, polyclonal antihuman thymocyte globulins was administered. An alternative approach for pharmacological immunosuppression was T cell depletion (positive CD34 + cell selection, negative selection, E-rosetting, monoclonal antibodies).
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Treatment of acute GVHD
Glucocorticoids: Most centres agree to the intravenous application of methylprednisolone given in three divided doses per day. 29, 30 If gastrointestinal intake and adequate absorption is possible, the drug can be given orally. Glucocorticoid therapy should be tapered off according to the response of GVHD. The following suggestions were supported (for details of agreement see Table 2 ).
Grade I: non-malignant disease, adjustment of CsA to FPIA levels 100-150 ng/ml prednisolone 2 mg/kg/day; malignant disease (MSD), adjustment of CsA to FPIA levels 100-150 ng/ml.
Grade II: all patients, adjustment of CsA to FPIA levels 100-150 ng/ml prednisolone 2 mg/kg/day.
Grade III/IV: all patients, adjustment of CsA to FPIA levels 150-250 ng/ml prednisolone 2 mg/kg/day.
If GVHD does not improve within 3-5 days: prednisolone 5 mg/kg/day. 
Additional drugs as options for second-line treat
Treatment of chronic GVHD
Most centres agreed to the use of either CsA or prednisolone in cases of limited GVHD, using the above mentioned methods. In patients with extensive chronic GVHD, a combination of both drugs is being used. If toxic problems occur, the two drugs are administered alternately. (For details see Table 3 .)
Use of corticosteroids in chronic GVHD:
The majority of experts prefer daily prednisolone, ie 2 mg/kg/day (starting dose) given in three divided doses. The second most frequently used regimen is the one giving alternate doses: on even days 2 mg/kg/day, on odd days 1 mg/kg/day, and step-by-step reduction to 0 mg/kg/day. 38 Only a few paediatric centres have experience with socalled pulse therapy, which consists of high doses of corticosteroids (eg 20 mg/kg/day) given for a short time (3-5 days). After that no steroid medication is given for a few weeks. 39 A dose reduction or tapering of dose is recommended in cases of improved or resolved cGVHD.
Second-line treatment for extensive cGVHD
If the first-line therapy failed to result in noticeable improvement of severe chronic GVHD, investigational agents might be tried. 
Discussion
Bearing in mind that it would have been much easier to solely describe survey results, the authors aimed to include current clinical considerations which are definitely not covered by solid scientific evidence. The reason why no binding recommendations emerged from these proposals lies in the fact that for many of the modes of treatment in children no conclusive published data are available.
As all the representatives of the EBMT WP-PD and the IBFM-SG BMT handed in their proposals after having discussed the issue with their members, the results are likely to reflect the current opinion of these groups about the issue in question. The decision as to which mode of GVHD prophylaxis should be used is influenced by various factors. Younger patients develop GVHD less frequently than do older recipients of allogeneic stem cells 47 and the disease is usually less severe than in adults. 48 Additionally, the thymus environment may play a more favourable role in making the new immune system tolerant. 49 The most important influence on the occurrence of GVHD appears to be the degree of HLA disparity between patient and stem cell donor. 50 Patients who receive stem cells from HLA-identical sibling donors have a lower risk of developing severe GVHD than do patients who receive grafts from unrelated or HLA-mismatched donors. 51 However, there are reports suggesting no difference in survival between HLA matched sibling donors and non-identical donors. 52 Not only do the above-mentioned factors influence the incidence and severity of GVHD, but the dose duration and type of the selected prophylaxis also play a role. 53, 54 To make proposals for GVHD prophylaxis, we have arbitrarily defined the following groups of patients. Children with non-malignant diseases should not experience GVHD. Hence, a relatively high dose for prophylaxis is mandatory for this group of patients. Although the EBMT working party for inborn errors in general recommends T cell depletion for patients with congenital abnormalities and HLA non-identical donors, only 60% of the responses supported this idea as an alternative approach in stem cell transplantation from mismatched or unrelated donors for patients with non-malignant disease. The reason for this may be that the matter was addressed too globally and that the differences between the various types of non-identical donors were not considered. More information is needed to clarify this aspect.
A large number of patients who undergo SCT in childhood are patients with leukaemia at high risk of relapse. This group might benefit from a strong GVL effect and therefore mild GVHD prophylaxis should be given. 55 So far, few studies have investigated two different CsA regimens in a randomised manner. 56 Therefore, we proposed the most frequently used starting dose of 3 mg/kg/day CsA. Trough level monitoring should prevent nephrotoxicity and confirm adequate immunosuppressive drug levels. It is likely that serum CsA concentration influences the level of immunosuppression and that low CsA concentrations can cause more severe GVHD. [57] [58] [59] However, there are no uniform strategies for adjustment of CsA levels and the individual centres follow their own regulations. Route of CsA administration, policy of adjusting the dose according to blood levels and the oral mode of application were not subjects of this survey and should be determined within the different co-operative study designs.
However, giving lower doses of CsA to young patients who are at high risk of leukaemic relapse is currently being discussed. Recently performed clinical trials 60 may clarify the relative efficacy of this approach with the aim of obtaining a better GVL effect. Since patients who have received transplants from non-identical donors bear an increased risk of GVHD, most European groups support the idea that after transplantation from alternative donors, patients should receive intensive pharmacological immunosuppression.
The proposal of giving patients under or over 16 years a different GVHD prophylaxis is not well proven and has only been reported in a non-randomised trial. 61 However, it appears to be an acceptable compromise for most of the participating groups.
It should be noted that most groups agreed to the proposed mode of MTX use. 62 The addition of MTX to the CsA prophylaxis delays recovery of bone marrow function and may increase gastrointestinal and liver toxicity. 63 Thus, giving folinic to reduce this side-effect was widely accepted.
Use of ALG received a lot of feedback. Several groups suggested giving different preparations. As the bioavailability differs between the drugs mentioned, 64 further details concerning dosage and route of administration should be discussed.
This first attempt to provide standard GVHD therapy in children should help to reduce heterogeneity in results obtained by different practices. Acute GVHD Ͼgrade I is treated with different preparations of steroids. As there are no proven benefits of very high doses of methylprednisolone, 65 most paediatricians tend to start treatment with doses of about 2 mg/kg/day, given in three divided doses. In cases of persistent or worsening GVHD, the prednisolone dose is usually increased to 5 mg/kg. However, especially in patients with leukaemia, many paediatricians recommend reducing the immunosuppression as fast as possible, so that the GVL effect is not compromised or lost. Therapy-resistant GVHD in children may be treated with ATG or ALG, 66 but other medications are also given in different doses. Novel drugs are MMF and tacrolimus, although publications describing the use of these agents in children are currently scarce. 67 In severe cases of gut GVHD, octreotid 68 is used. In chronic GVHD we proposed three different routes for administering prednisolone, of which only two are commonly used in the treatment of long-term chronic GVHD. In severe cases, extracorporal photoimmunotherapy represents a new therapeutic option and is used in several centres on a trial basis. In cases of chronic skin GVHD in children, PUVA therapy 69 is also used. Thalidomide 40 plays a certain role in resistant cGVHD.
The optimal use of immunosuppressive agents for both prevention and treatment of acute and chronic GVHD has not yet been found and defined for all patient groups. Thus, co-operation will be necessary to enable the value of the respective methods to be examined under controlled conditions, to find a way of making allogeneic stem cell transplantation in children more efficient, and to reduce the likelihood of side-effects.
